Hudes G - Search Results

1

The basic biology and immunobiology of renal cell carcinoma: considerations for the clinician.

Uzzo RG, Cairns P, Al-Saleem T, Hudes G, Haas N, Greenberg RE, Kolenko V. Uzzo RG, et al. Among authors: hudes g. Urol Clin North Am. 2003 Aug;30(3):423-36. doi: 10.1016/s0094-0143(03)00021-1. Urol Clin North Am. 2003. PMID: 12953746 Review.

2

Cutaneous metastases from genitourinary malignancies.

Mueller TJ, Wu H, Greenberg RE, Hudes G, Topham N, Lessin SR, Uzzo RG. Mueller TJ, et al. Among authors: hudes g. Urology. 2004 Jun;63(6):1021-6. doi: 10.1016/j.urology.2004.01.014. Urology. 2004. PMID: 15183939 Review.

3

Phase I clinical and pharmacologic trial of intravenous estramustine phosphate.

Hudes G, Haas N, Yeslow G, Gillon T, Gunnarsson PO, Ellman M, Nordle O, Eriksson B, Miller L, Cisar L, Kopreski M, Viaro D, Hartley-Asp B. Hudes G, et al. J Clin Oncol. 2002 Feb 15;20(4):1115-27. doi: 10.1200/JCO.2002.20.4.1115. J Clin Oncol. 2002. PMID: 11844837 Clinical Trial.

4

Phase II pilot study of combined chemohormonal therapy with doxorubicin and estramustine in metastatic prostate cancer.

Haas NB, Manola J, Hudes G, Citrin DL, Kies MS, Davis TE; Eastern Cooperative Oncology Group Study PH882. Haas NB, et al. Among authors: hudes g. Am J Clin Oncol. 2000 Dec;23(6):589-92. doi: 10.1097/00000421-200012000-00012. Am J Clin Oncol. 2000. PMID: 11202803 Clinical Trial.

5

Phase I trial of weekly paclitaxel plus oral estramustine phosphate in patients with hormone-refractory prostate cancer.

Haas N, Roth B, Garay C, Yeslow G, Entmacher M, Weinstein A, Rogatko A, Babb J, Minnitti C, Flinker D, Gillon T, Hudes G. Haas N, et al. Among authors: hudes g. Urology. 2001 Jul;58(1):59-64. doi: 10.1016/s0090-4295(01)01011-1. Urology. 2001. PMID: 11445480 Clinical Trial.

6

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ; Global ARCC Trial. Hudes G, et al. N Engl J Med. 2007 May 31;356(22):2271-81. doi: 10.1056/NEJMoa066838. N Engl J Med. 2007. PMID: 17538086 Free article. Clinical Trial.

7

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

Rini BI, Wilding G, Hudes G, Stadler WM, Kim S, Tarazi J, Rosbrook B, Trask PC, Wood L, Dutcher JP. Rini BI, et al. Among authors: hudes g. J Clin Oncol. 2009 Sep 20;27(27):4462-8. doi: 10.1200/JCO.2008.21.7034. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652060 Clinical Trial.

8

Estramustine-based chemotherapy.

Hudes G. Hudes G. Semin Urol Oncol. 1997 Feb;15(1):13-9. Semin Urol Oncol. 1997. PMID: 9050135 Review.

9

Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma.

Wong YN, Litwin S, Vaughn D, Cohen S, Plimack ER, Lee J, Song W, Dabrow M, Brody M, Tuttle H, Hudes G. Wong YN, et al. Among authors: hudes g. J Clin Oncol. 2012 Oct 1;30(28):3545-51. doi: 10.1200/JCO.2012.41.9572. Epub 2012 Aug 27. J Clin Oncol. 2012. PMID: 22927525 Free PMC article. Clinical Trial.

10

Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment.

Hanks GE, Hanlon AL, Hudes G, Lee WR, Suasin W, Schultheiss TE. Hanks GE, et al. Among authors: hudes g. J Clin Oncol. 1996 Apr;14(4):1093-7. doi: 10.1200/JCO.1996.14.4.1093. J Clin Oncol. 1996. PMID: 8648362

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

175 results

Search Page

Filters